目的基于全转录组测序探讨小鼠肝细胞癌(hepatocellular carcinoma,HCC)组织中miR-122-5p和miR-27b-3p调控DNA拓扑异构酶2-a(DNA topoisomerase 2-alpha,Top2a)异常表达的可能调控机制。方法通过构建小鼠HCC模型、实时荧光定量PCR(RT-qP...目的基于全转录组测序探讨小鼠肝细胞癌(hepatocellular carcinoma,HCC)组织中miR-122-5p和miR-27b-3p调控DNA拓扑异构酶2-a(DNA topoisomerase 2-alpha,Top2a)异常表达的可能调控机制。方法通过构建小鼠HCC模型、实时荧光定量PCR(RT-qPCR)和全转录组测序等生物信息学手段,以及结合The Human Protein Atlas(人类蛋白质图谱数据库),分析Top2a在瘤体组织和正常肝组织中的差异表达,并进一步筛选与Top2a或其编码蛋白有PPI和靶标关系的差异(q<0.05,q为校正的P)表达基因和miRNA,分析其功能。构建Top2a编码蛋白的蛋白质-蛋白质互作图(PPI)和分析Top2a及相关基因参与的生物学功能。结果与对照组相比,瘤体组织中Top2a差异过表达(P<0.05),且存在87个与Top2a编码蛋白互作、差异表达的蛋白编码基因。GO功能富集显示,Top2a及相关基因主要存在于细胞核,且多数具有蛋白结合和DNA结合活性,参与RNA聚合酶Ⅱ启动子转录的正向调节、细胞对DNA损伤刺激的反应和染色体分离等生物学过程。同时,存在miR-27b-3p和miR-122-5p这2种靶向于Top2a的miRNA在瘤体组织中表达显著低于对照组织。Top2a基因在肝癌组织中RNA和蛋白质表达水平均高于正常肝组织,此外,Top2a基因低表达的肝癌患者的生存率明显高于高表达的患者。结论Top2a基因在HCC中过表达是其细胞抑制了miR-122-5p和miR-27b-3p表达的结果。而Top2a在细胞核内通过蛋白结合和DNA结合等活性,影响转录起始、DNA损伤刺激反应和染色体分离等生物学过程,则是其在HCC中发挥作用的分子机制。Top2a基因可能是预测肝癌预后的重要生物标志物,有一定的临床诊断价值。展开更多
BACKGROUND Cardiac tumors are rare and complex entities.Surgery represents the cornerstone of therapy,while the role of adjuvant treatment remains unclear and,in case of relapse or metastatic disease,the prognosis is ...BACKGROUND Cardiac tumors are rare and complex entities.Surgery represents the cornerstone of therapy,while the role of adjuvant treatment remains unclear and,in case of relapse or metastatic disease,the prognosis is very poor.Lack of prospective,randomized clinical trials hinders the generation of high level evidence for the optimal diagnostic workup and multimodal treatment of cardiac sarcomas.Herein,we describe the multidisciplinary clinical management and molecular characterization of a rare case of cardiac myxofibrosarcoma in an elderly woman.CASE SUMMARY A 73-year-old woman presented signs and symptoms of acute left-sided heart failure.Imaging examination revealed a large,left atrial mass.With suspicion of a myxoma,she underwent surgery,and symptoms were promptly relieved.Histology showed a cardiac myxofibrosarcoma,a rare histotype of cardiac sarcoma.Eight months later,disease unfortunately relapsed,and after a multidisciplinary discussion,a chemotherapy with doxorubicin and then gemcitabine was started,achieving partial radiologic and complete metabolic response,which was maintained up to 2 years and is still present.This report is focused on the entire clinical path of our patient from diagnosis to follow-up,through surgery and strategies adopted at relapse.Moreover,due to their rarity,very little is known about the molecular landscape of myxofibrosarcomas.Thus,we also performed and described preliminary genome analysis of the tumor tissue to get further insight on mechanisms involved in tumor growth,and to possibly unveil new clinically actionable targets.CONCLUSION We report a case of cardiac myxofibrosarcoma that achieved a very good prognosis due to an integrated surgical,cardiac and oncologic treatment strategy.展开更多
This study systematically evaluates the TCGA whole-transcriptome sequencing data of hepatocellular carcinoma （HCC） by comparing the global gene expression profiles between tumors and their corresponding non- tumorou...This study systematically evaluates the TCGA whole-transcriptome sequencing data of hepatocellular carcinoma （HCC） by comparing the global gene expression profiles between tumors and their corresponding non- tumorous liver tissue. Based on the differential gene expression analysis, we identified a number of novel dysregulated genes, in addition to those previously reported. Top-listing upregulated （CENPF and FOXM1） and downregulated （CLEC4G, CRHBP, and CLEC1B） genes were successfully validated using qPCR on our cohort of 65 pairs of human HCCs. Further examination for the mechanistic overview by subjecting significantly upregulated and downregulated genes to gene set enrichment analysis showed that different cellular pathways were involved. This study provides useful information on the transcriptomic landscape and molecular mechanism of hepatocarcinogenesis for development of new biomarkers and further in-depth characterization.展开更多
文摘目的基于全转录组测序探讨小鼠肝细胞癌(hepatocellular carcinoma,HCC)组织中miR-122-5p和miR-27b-3p调控DNA拓扑异构酶2-a(DNA topoisomerase 2-alpha,Top2a)异常表达的可能调控机制。方法通过构建小鼠HCC模型、实时荧光定量PCR(RT-qPCR)和全转录组测序等生物信息学手段,以及结合The Human Protein Atlas(人类蛋白质图谱数据库),分析Top2a在瘤体组织和正常肝组织中的差异表达,并进一步筛选与Top2a或其编码蛋白有PPI和靶标关系的差异(q<0.05,q为校正的P)表达基因和miRNA,分析其功能。构建Top2a编码蛋白的蛋白质-蛋白质互作图(PPI)和分析Top2a及相关基因参与的生物学功能。结果与对照组相比,瘤体组织中Top2a差异过表达(P<0.05),且存在87个与Top2a编码蛋白互作、差异表达的蛋白编码基因。GO功能富集显示,Top2a及相关基因主要存在于细胞核,且多数具有蛋白结合和DNA结合活性,参与RNA聚合酶Ⅱ启动子转录的正向调节、细胞对DNA损伤刺激的反应和染色体分离等生物学过程。同时,存在miR-27b-3p和miR-122-5p这2种靶向于Top2a的miRNA在瘤体组织中表达显著低于对照组织。Top2a基因在肝癌组织中RNA和蛋白质表达水平均高于正常肝组织,此外,Top2a基因低表达的肝癌患者的生存率明显高于高表达的患者。结论Top2a基因在HCC中过表达是其细胞抑制了miR-122-5p和miR-27b-3p表达的结果。而Top2a在细胞核内通过蛋白结合和DNA结合等活性,影响转录起始、DNA损伤刺激反应和染色体分离等生物学过程,则是其在HCC中发挥作用的分子机制。Top2a基因可能是预测肝癌预后的重要生物标志物,有一定的临床诊断价值。
文摘BACKGROUND Cardiac tumors are rare and complex entities.Surgery represents the cornerstone of therapy,while the role of adjuvant treatment remains unclear and,in case of relapse or metastatic disease,the prognosis is very poor.Lack of prospective,randomized clinical trials hinders the generation of high level evidence for the optimal diagnostic workup and multimodal treatment of cardiac sarcomas.Herein,we describe the multidisciplinary clinical management and molecular characterization of a rare case of cardiac myxofibrosarcoma in an elderly woman.CASE SUMMARY A 73-year-old woman presented signs and symptoms of acute left-sided heart failure.Imaging examination revealed a large,left atrial mass.With suspicion of a myxoma,she underwent surgery,and symptoms were promptly relieved.Histology showed a cardiac myxofibrosarcoma,a rare histotype of cardiac sarcoma.Eight months later,disease unfortunately relapsed,and after a multidisciplinary discussion,a chemotherapy with doxorubicin and then gemcitabine was started,achieving partial radiologic and complete metabolic response,which was maintained up to 2 years and is still present.This report is focused on the entire clinical path of our patient from diagnosis to follow-up,through surgery and strategies adopted at relapse.Moreover,due to their rarity,very little is known about the molecular landscape of myxofibrosarcomas.Thus,we also performed and described preliminary genome analysis of the tumor tissue to get further insight on mechanisms involved in tumor growth,and to possibly unveil new clinically actionable targets.CONCLUSION We report a case of cardiac myxofibrosarcoma that achieved a very good prognosis due to an integrated surgical,cardiac and oncologic treatment strategy.
文摘目的在急性单核细胞白血病细胞(THP-1)水平建立Ⅲ型登革病毒(Dengue virus typeⅢ,DENV-3,DV-3)感染和抗体依赖性增强(antibody dependent enhancement,ADE)感染模型,探讨胞内长链非编码RNA(long non-coding RNA,LncRNA)的差异性表达,绘制竞争性内源RNA(competitive endogenous RNA,CeRNA)调控网络并进行LncRNA翻译功能预测。方法DENV-3感染C6/36细胞6 d后,收获培养上清,采用CCID50法测定病毒滴度,并通过PCR进行型别以及基因组全长扩增鉴定;扩增DENV-3标准质粒,PCR鉴定,绘制标准曲线;将THP-1细胞分为阴性对照(THP-1)、直接感染(DV-3)、ADE及空白对照[1640(-)]组,感染48 h后提取胞内总RNA,测定病毒拷贝数;通过全转录组测序技术,对THP-1 vs DENV-3、THP-1 vs ADE、DENV-3 vs ADE各组中上调和下调前5个的LncRNA进行CeRNA调控网络构建,并分析其编码蛋白的功能。结果DENV-3感染C6/36细胞3 d后有明显的细胞融合、空泡和脱落;病毒滴度约为1.0×10^(4.64)PFU/mL,PCR特异引物鉴定为DENV-3,获得病毒完整的基因序列;ADE组胞内病毒核酸拷贝数明显高于DV-3组和空白对照组;在THP-1 vs DENV-3中,预测到人细胞黏附蛋白相互作用蛋白(cytohesin interacting protein,CYTIP)的表达量出现上调;在THP-1 vs ADE中,预测到驱动蛋白家族成员5A(kinesin family 5A,KIF5A)的表达量下调;在DENV-3 vs ADE中,预测到簇分化抗原9(cluster differentiation antigen 9,CD9)和胰岛素样生长因子2(insulin like growth factor 2,IGF2)的表达量上调。这些差异性的LncRNA均具有开放阅读框(open reading frame,ORF),除了Lnc-SH3BP1和Lnc-RPL41以外,其余的LncRNA均具有内部核糖体结合位点(internal ribosome binding site,IRES)。结论在DENV-3感染THP-1细胞及其介导的ADE感染中,LncRNA的表达发生了明显的差异性改变,且可能通过多种生物学功能调控感染的进程,有助于更深层次理解ADE感染的发生机制。
文摘This study systematically evaluates the TCGA whole-transcriptome sequencing data of hepatocellular carcinoma （HCC） by comparing the global gene expression profiles between tumors and their corresponding non- tumorous liver tissue. Based on the differential gene expression analysis, we identified a number of novel dysregulated genes, in addition to those previously reported. Top-listing upregulated （CENPF and FOXM1） and downregulated （CLEC4G, CRHBP, and CLEC1B） genes were successfully validated using qPCR on our cohort of 65 pairs of human HCCs. Further examination for the mechanistic overview by subjecting significantly upregulated and downregulated genes to gene set enrichment analysis showed that different cellular pathways were involved. This study provides useful information on the transcriptomic landscape and molecular mechanism of hepatocarcinogenesis for development of new biomarkers and further in-depth characterization.
